Compare Stocks: ANVS, ALXO, ABOS, and IPHA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$2.26 -0.4%	$2.49	$1.50 ▼ $3.60	$164.16M	0.33	N/A	1.80 million shs
ALXO ALX Oncology	$1.10 -2.7%	$1.56	$0.86 ▼ $2.66	N/A	N/A	N/A	3.22 million shs
ANVS Annovis Bio	$1.01 +5.0%	$1.31	$0.93 ▼ $5.50	$40.84M	1.23	N/A	912,823 shs
IPHA Innate Pharma	$1.48 +1.4%	$1.80	$1.17 ▼ $2.71	N/A	N/A	N/A	16,815 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	-0.44%	+12.16%	+0.89%	+7.11%	+2.73%
ALXO ALX Oncology	-2.65%	-11.29%	-16.03%	-43.44%	-35.29%
ANVS Annovis Bio	+5.35%	+2.45%	-23.57%	-41.06%	-52.82%
IPHA Innate Pharma	+1.37%	-6.21%	-12.94%	-18.68%	-37.82%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$2.26 -0.4%	$2.49	$1.50 ▼ $3.60	$164.16M	0.33	N/A	1.80 million shs
ALXO ALX Oncology	$1.10 -2.7%	$1.56	$0.86 ▼ $2.66	N/A	N/A	N/A	3.22 million shs
ANVS Annovis Bio	$1.01 +5.0%	$1.31	$0.93 ▼ $5.50	$40.84M	1.23	N/A	912,823 shs
IPHA Innate Pharma	$1.48 +1.4%	$1.80	$1.17 ▼ $2.71	N/A	N/A	N/A	16,815 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	-0.44%	+12.16%	+0.89%	+7.11%	+2.73%
ALXO ALX Oncology	-2.65%	-11.29%	-16.03%	-43.44%	-35.29%
ANVS Annovis Bio	+5.35%	+2.45%	-23.57%	-41.06%	-52.82%
IPHA Innate Pharma	+1.37%	-6.21%	-12.94%	-18.68%	-37.82%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	2.60	Moderate Buy	$7.00	209.73% Upside
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	318.18% Upside
ANVS Annovis Bio	2.25	Hold	$12.00	1,094.03% Upside
IPHA Innate Pharma	2.67	Moderate Buy	$6.67	350.45% Upside

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, ABOS, and IPHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	ABOS Acumen Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/2/2026	ANVS Annovis Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/22/2026	IPHA Innate Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/21/2026	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/17/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/17/2026	ABOS Acumen Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/17/2026	IPHA Innate Pharma	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$9.00
9/16/2026	ABOS Acumen Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$8.00
9/15/2026	ABOS Acumen Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$4.00 ➝ $5.00
9/2/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$8.00 ➝ $7.00

(Data available from 10/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	N/A	-$1.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ALXO ALX Oncology	N/A	-$1.13	N/A	N/A	N/A	N/A	N/A	N/A	11/6/2026 (Estimated)
ANVS Annovis Bio	N/A	-$1.79	N/A	N/A	N/A	N/A	N/A	N/A	11/11/2026 (Estimated)
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ANVS, ALXO, ABOS, and IPHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ANVS Annovis Bio	-$0.30	N/A	N/A	N/A	N/A	N/A
11/6/2026	Q3 2026	ALXO ALX Oncology	-$0.15	N/A	N/A	N/A	N/A	N/A
10/26/2026	Q3 2026	ABOS Acumen Pharmaceuticals	-$0.3886	-$0.35	+$0.0386	-$0.35	N/A	N/A
8/14/2026	Q2 2026	ANVS Annovis Bio	-$0.4533	-$0.40	+$0.0533	-$0.40	N/A	N/A
8/12/2026	Q2 2026	ABOS Acumen Pharmaceuticals	-$0.3593	-$0.45	-$0.0907	-$0.45	N/A	N/A
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
ALXO ALX Oncology	97.97%
ANVS Annovis Bio	15.83%
IPHA Innate Pharma	0.16%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	10.20%
ALXO ALX Oncology	12.40%
ANVS Annovis Bio	15.92%
IPHA Innate Pharma	31.89%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	61	72.32 million	64.94 million	Optionable
ALXO ALX Oncology	48	N/A	121.13 million	Optionable
ANVS Annovis Bio	7	42.68 million	35.89 million	Optionable
IPHA Innate Pharma	163	N/A	76.09 million	Not Optionable

ANVS, ALXO, ABOS, and IPHA Headlines

Recent News About These Companies

Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027

October 27 at 3:41 AM | finance.yahoo.com

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Stock Has Average Price Target of $6.67 According to Analysts

October 25 at 6:13 AM | marketbeat.com

Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference

October 21, 2026 | businesswire.com

Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update

October 20, 2026 | businesswire.com

Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround

October 8, 2026 | zacks.com

Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)

October 5, 2026 | zacks.com

Innate Pharma SA - Depositary receipt price target increased by 27.91% to $8.22

October 2, 2026 | msn.com

Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know

September 23, 2026 | zacks.com

Innate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track?

September 23, 2026 | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Innate Pharma (IPHA) and Alnylam Pharma (ALNY)

September 22, 2026 | theglobeandmail.com

Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript

September 18, 2026 | aol.comA

Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript

September 17, 2026 | seekingalpha.com

Innate Pharma Reports H1 Loss Narrows; Advances Lacutamab And IPH4502

September 17, 2026 | rttnews.com

Innate Pharma Reports First Half 2026 Business Update and Financial Results

September 17, 2026 | streetinsider.com

Sobi and Innate announce partnership is now effective following completion of closing conditions

September 17, 2026 | finance.yahoo.com

Innate Pharma, Sobi Partnership Becomes Effective

September 17, 2026 | finance.yahoo.com

Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions

September 16, 2026 | finance.yahoo.com

Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update

September 10, 2026 | finance.yahoo.com

Innate Pharma participera à la H.C. Wainwright 28th annual global investment conference

September 3, 2026 | afp.comA

Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript

August 14, 2026 | seekingalpha.com

Innate Pharma Announces Conference Call and Webcast

August 14, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, ABOS, and IPHA Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$2.26 -0.01 (-0.44%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$2.29 +0.03 (+1.46%)

As of 07:24 AM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

ALX Oncology NASDAQ:ALXO

$1.10 -0.03 (-2.65%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$1.07 -0.03 (-2.64%)

As of 07:00 AM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Annovis Bio NYSE:ANVS

$1.00 +0.05 (+5.02%)

Closing price 10/27/2026 03:59 PM Eastern

Extended Trading

$1.00 0.00 (-0.50%)

As of 07:07 AM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Innate Pharma NASDAQ:IPHA

$1.48 +0.02 (+1.37%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$1.49 +0.01 (+0.95%)

As of 04:00 AM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, ABOS, and IPHA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANVS, ALXO, ABOS, and IPHA Earnings

Compare Dividends

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANVS, ALXO, ABOS, and IPHA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, ABOS, and IPHA Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

ALX Oncology NASDAQ:ALXO

Annovis Bio NYSE:ANVS

Innate Pharma NASDAQ:IPHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, ABOS, and IPHA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANVS, ALXO, ABOS, and IPHA Earnings

Compare Dividends

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANVS, ALXO, ABOS, and IPHA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, ABOS, and IPHA Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

ALX Oncology NASDAQ:ALXO

Annovis Bio NYSE:ANVS

Innate Pharma NASDAQ:IPHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools